Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

被引：54

作者：

Levine, Bruce L. ^{[1
,2
]}

Pasquini, Marcelo C. ^{[3
,4
]}

Connolly, John E. ^{[5
]}

Porter, David L. ^{[6
]}

Gustafson, Michael P. ^{[7
]}

Boelens, Jaap J. ^{[8
]}

Horwitz, Edwin M. ^{[9
]}

Grupp, Stephan A. ^{[10
,11
]}

Maus, Marcela V. ^{[12
,13
]}

Locke, Frederick L. ^{[14
]}

Ciceri, Fabio ^{[15
]}

Ruggeri, Annalisa ^{[16
]}

Snowden, John ^{[17
,18
]}

Heslop, Helen E. ^{[19
,20
,21
]}

Mackall, Crystal L. ^{[22
,23
,24
,25
]}

June, Carl H. ^{[1
,2
,26
]}

Sureda, Anna M. ^{[27
]}

Perales, Miguel-Angel ^{[28
,29
]}

机构：

[1] Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA

[3] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI USA

[4] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA

[5] Parker Inst Canc Immunotherapy, San Francisco, CA USA

[6] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Cell Therapy & Transplant, Philadelphia, PA USA

[7] Mayo Clin Arizona, Dept Lab Med & Pathol, Phoenix, AZ USA

[8] Mem Sloan Kettering Canc Ctr, Transplantat & Cellular Therapy Serv, New York, NY USA

[9] Emory Univ, Winship Canc Inst, Aflac Canc & Blood Disorders Ctr, Sch Med,Dept Pediat, Atlanta, GA USA

[10] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA USA

[11] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA USA

[12] Mass Gen Canc Ctr, Cellular Immunotherapy Program, Cambridge, MA USA

[13] Harvard Med Sch, Cambridge, MA USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunoth, Tampa, FL USA

[15] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst Milano, Milan, Italy

[16] IRCCS San Raffaele Sci Inst, Hematol & BMT Unit, Milan, Italy

[17] Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, England

[18] Univ Sheffield, Sch Med & Populat Hlth, Div Clin Med, Sheffield, England

[19] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX USA

[20] Texas Childrens Hosp, Houston, TX USA

[21] Houston Methodist Hosp, Houston, TX USA

[22] Stanford Univ, Stanford Canc Inst, Ctr Canc Cell Therapy, Palo Alto, CA USA

[23] Stanford Univ, Dept Pediat, Palo Alto, CA USA

[24] Stanford Univ, Dept Med, Palo Alto, CA USA

[25] Parker Inst Canc Immunotherapy, Palo Alto, CA USA

[26] Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA USA

[27] Univ Barcelona, Inst Catala Oncol LHospitalet, Clin Hematol Dept, IDIBELL, Barcelona, Spain

[28] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplantat Serv, Dept Med, New York, NY USA

[29] Weill Cornell Med Coll, Dept Med, New York, NY USA

来源：

NATURE MEDICINE | 2024年 / 30卷 / 03期

关键词：

D O I：

10.1038/s41591-023-02767-w

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

引用

页码：338 / 341

页数：4

共 50 条

[1] Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Bruce L. Levine
Marcelo C. Pasquini
John E. Connolly
David L. Porter
Michael P. Gustafson
Jaap J. Boelens
Edwin M. Horwitz
Stephan A. Grupp
Marcela V. Maus
Frederick L. Locke
Fabio Ciceri
Annalisa Ruggeri
John Snowden
Helen E. Heslop
Crystal L. Mackall
Carl H. June
Anna M. Sureda
Miguel-Angel Perales
[J]. Nature Medicine, 2024, 30 : 338 - 341
[2] Secondary Malignancies after CAR-T Cell Therapy
Rudek, Loreen Sophie
Alakus, Hakan
[J]. ONKOLOGIE, 2024,
[3] Resistance and recurrence of malignancies after CAR-T cell therapy
Zeng, Wanying
Zhang, Pumin
[J]. EXPERIMENTAL CELL RESEARCH, 2022, 410 (02)
[4] CAR-T Cell Therapy for T-Cell Malignancies
Testa, Ugo
Chiusolo, Patrizia
Pelosi, Elvira
Castelli, Germana
Leone, Giuseppe
[J]. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2024, 16 (01)
[5] Toxicities following CAR-T therapy for hematological malignancies
Hernani, Rafael
Benzaquen, Ana
Solano, Carlos
[J]. CANCER TREATMENT REVIEWS, 2022, 111
[6] Current state of CAR-T therapy for T-cell malignancies
Luo, Liangkui
Zhou, Xuan
Zhou, Lijuan
Liang, Zhao
Yang, Jilong
Tu, Sanfang
Li, Yuhua
[J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[7] Current state of CAR-T therapy for T-cell malignancies
Luo, Liangkui
Zhou, Xuan
Zhou, Lijuan
Liang, Zhao
Yang, Jilong
Tu, Sanfang
Li, Yuhua
[J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[8] Current Progress in CAR-T Cell Therapy for Hematological Malignancies
Han, Donglei
Xu, Zenghui
Zhuang, Yuan
Ye, Zhenlong
Qian, Qijun
[J]. JOURNAL OF CANCER, 2021, 12 (02): : 326 - 334
[9] CAR-T for the treatment of T cell malignancies
DiPersio, John F.
[J]. MEDICINE, 2019, 98 (26)
[10] The journey of CAR-T therapy in hematological malignancies
Lu, Junru
Jiang, Guan
[J]. MOLECULAR CANCER, 2022, 21 (01)

← 1 2 3 4 5 →